Articles On Imugene (ASX:IMU)

The agreement with Bell Potter further strengthens the company’s financial position building on the existing cash balance of $30.1 million as of June 30, 2020.

Summary Imugene has received first ethics approval in the US to start PD1-Vaxx’s Phase I trial. The approval has been granted to Hackensack University Medical Center, based in New Jersey USA. Imugene has planned to proceed with the sit...

Site activation and patient recruitment will proceed after FDA IND approval scheduled for the fourth quarter of 2020.

In a latest update, the biotech company Imugene Limited (ASX:IMU) has published its Annual Report for the year ended 30th June 2020 on the ASX. The financial year 2020 has been a remarkable one for Imugene, experiencing significant change a...

The stock of Australian clinical-stage immuno-oncology company, Imugene Limited (ASX:IMU) traded ~1.8 per cent higher on 21st August 2020 following the release of a significant update on PD1-Vaxx’s third ethics approval for Phase 1 trial....

The ethics approval represents the third independent review of PD1-Vaxx pre-clinical safety and efficacy data.

Summary Imugene received US FDA guidance on the development pathway for VAXinia (CF33-hNIS). FDA provided feedback on adaptive Phase 1 clinical development plans and non-clinical development pathway for VAXinia. The Company has initiat...

The FDA provided feedback on the non-clinical development pathway and adaptive phase one clinical development plans for VAXinia, IMU’s lead oncolytic virotherapy for treatment of solid tumours.

“We’re sorry.” Two words rarely heard from company boards, and even more rarely in annual reports. But Lev Mizikozsky, chairman of sunscreen seller Advance Nanotek (ASX:ANO), is a man who doesn’t trend the conventional path. Mizikovsky’s ap...

Last month, Imugene received Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx in Australia.

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) marked an uptick of ~22.6 per cent to $0.065 on ASX following the release of its solid June quarterly results on 27 July 2020. As at 11:50 AM AEST on 29 July 2020, IMU is tra...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

Summary Imugene has received a second human research ethics approval to kickstart its Phase I clinical trial of PD1- Vaxx in Australia. While the second ethics approval has been received by Sydney-based Macquarie University, Chris O’Bri...

Immuno-oncology company Imugene (ASX: IMU) received a timely regulatory boost courtesy of a second Human Research Ethics Committee (HREC) approval to commence a Phase I clinical trial of its checkpoint immunotherapy candidate PD1-Vaxx, in A...

The ethics approval represents the second independent review of PD-1 Vaxx pre-clinical safety and efficacy.

ShareCafeAustralia…1 Hour In…ASX Up 2 Points – Bluescope (-1.5%); expects FY earnings to be around $560m vs previous guidance of $302m for the 1H. The drop is due to an impairment charge of $200m. – Imugene (+8%); has received a second Huma...

A quick wrap of the ASX’s key winners and losers on Wednesday, July 15. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 987 stocks rose, 400 d...

Summary Imugene has attained human research ethics approval for commencement of PD1-Vaxx’ Phase 1 clinical trial in Australia. Sydney-based comprehensive cancer hospital, Chris O’Brien Lifehouse is the first one to attain ethics app...

Ethics approval is confirmation Imugene has completed all the necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to commence human clinical trials.

ShareCafeAustralia…One Hour In…ASX Down 47 Points – Breville Group (+4%); big broker upgrade. – Imugene (+6%); receives ethics approval to start the PD1-VAXX trial. – Marley Spoon (+6%); COVID has been a blessing for these guys. Seems there...

Summary Backed by an international leadership team with extensive commercialisation expertise in the sector, Imugene has developed a robust product portfolio, comprising four potential drugs. In 2020, Imugene intends to progress with Ph...

Summary Imugene?s preclinical research associated with mimotope vaccines targeting immune checkpoint inhibitors published in ?Frontiers in Immunology? journal. Research discovered that mimotope peptides when included in Imugene?s exclus...

The research has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform generate antibodies.

HER-Vaxx is Imugene’s lead cancer immunotherapy candidate and is currently treating patients in a phase 2 study in gastric cancer.

Clinical stage Australian immuno-oncology company, Imugene Limited (ASX:IMU) is set to kickstart two clinical trials with B-cell immunotherapy - PD1-Vaxx and oncolytic virotherapy CF33 this year. Recently, Imugene presented presentations on...

The Independent Data Monitoring Committee (IDMC) members have no safety concerns regarding B-cell immunotherapy HER-Vaxx, and biotech player Imugene Limited (ASX:IMU) can continue with its Phase 2 trial without modification, confirmed IDMC...

The Independent Data Monitoring Committee’s role is to review study data and conduct a formal independent review of key data such as deaths, adverse reactions and laboratory results.

Australia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) will present the clinical plans for the initial Phase 1 trials of its oncolytic virus, Vaxinia (CF33-hNIS) and its PD-1 targeting cancer immunotherapy, PD1-Vaxx a...

The first-in-human phase 1 study of Vaxinia is in patients with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.

The company is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) is actively implementing risk mitigation and business continuity strategies amidst the global COVID-19 pandemic to continue with its planned activities....

The company is developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

The company is developing a range of treatments to activate the immune system of cancer patients.

The ASX is cracking down on biotech and health companies disclosures around possible coronavirus-linked products. Yesterday TBG Diagnostics (ASX:TDL) was suspended as the ASX looks into why it waited until Wednesday to reveal that a COVID19...

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

The clinical stage immuno-oncology company is developing a range of new treatments seeking to activate the immune system of cancer patients.

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has released another set of robust operational results for the half-year ended 31st December 2019. It was certainly a remarkable half-year for the biote...

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

The company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC).

Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx

Pre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finish as well as processes completed by FDA inspected and qualified contract manufacturing organisations in the US.

Imugene (IMU) will trial its cancer immunotherapy treatment, PD10Vaxx, to patients in North America and Australia The treatment will be trialled on patients with non-small cell lung cancer, which is the most common type of lung cancer The...

Immuno-oncology company Imugene (ASX: IMU) is set to advance its PD1-Vaxx cancer immunotherapy by trialling the treatment in patients with non-small cell lung cancer. In an update to the market, the company said it plans to conduct a new st...

28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.

A Smash Hit by Imugene: Received Core US Patent for HER-Vaxx

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

The patent provides method of composition and method of use protection to 2036.